Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.
Journal
Signal transduction and targeted therapy
ISSN: 2059-3635
Titre abrégé: Signal Transduct Target Ther
Pays: England
ID NLM: 101676423
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
01
06
2023
accepted:
06
08
2024
revised:
21
07
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
Type 2 diabetes (T2D) is a disease characterized by heterogeneously progressive loss of islet β cell insulin secretion usually occurring after the presence of insulin resistance (IR) and it is one component of metabolic syndrome (MS), and we named it metabolic dysfunction syndrome (MDS). The pathogenesis of T2D is not fully understood, with IR and β cell dysfunction playing central roles in its pathophysiology. Dyslipidemia, hyperglycemia, along with other metabolic disorders, results in IR and/or islet β cell dysfunction via some shared pathways, such as inflammation, endoplasmic reticulum stress (ERS), oxidative stress, and ectopic lipid deposition. There is currently no cure for T2D, but it can be prevented or in remission by lifestyle intervention and/or some medication. If prevention fails, holistic and personalized management should be taken as soon as possible through timely detection and diagnosis, considering target organ protection, comorbidities, treatment goals, and other factors in reality. T2D is often accompanied by other components of MDS, such as preobesity/obesity, metabolic dysfunction associated steatotic liver disease, dyslipidemia, which usually occurs before it, and they are considered as the upstream diseases of T2D. It is more appropriate to call "diabetic complications" as "MDS-related target organ damage (TOD)", since their development involves not only hyperglycemia but also other metabolic disorders of MDS, promoting an up-to-date management philosophy. In this review, we aim to summarize the underlying mechanism, screening, diagnosis, prevention, and treatment of T2D, especially regarding the personalized selection of hypoglycemic agents and holistic management based on the concept of "MDS-related TOD".
Identifiants
pubmed: 39353925
doi: 10.1038/s41392-024-01951-9
pii: 10.1038/s41392-024-01951-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
262Subventions
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82170830
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82170830
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82170830
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82170830
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82170830
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82170830
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82170830
Informations de copyright
© 2024. The Author(s).
Références
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).
Lonardo, A., Nascimbeni, F., Mantovani, A. & Targher, G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence. J. Hepatol. 68, 335–352 (2018).
pubmed: 29122390
doi: 10.1016/j.jhep.2017.09.021
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).
doi: 10.1016/S0140-6736(23)01301-6
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).
doi: 10.1016/S0140-6736(20)30925-9
Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pr. 183, 109119 (2022).
doi: 10.1016/j.diabres.2021.109119
Kautzky-Willer, A., Harreiter, J. & Pacini, G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr. Rev. 37, 278–316 (2016).
pubmed: 27159875
pmcid: 4890267
doi: 10.1210/er.2015-1137
Bonnefond, A. & Froguel, P. Rare and common genetic events in type 2 diabetes: what should biologists know? Cell Metab. 21, 357–368 (2015).
pubmed: 25640731
doi: 10.1016/j.cmet.2014.12.020
Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. Diabetologia 62, 3–16 (2019).
pubmed: 30171279
doi: 10.1007/s00125-018-4711-2
Liu, W. et al. Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: an age-period-cohort analysis. Diabetes Obes. Metab. 26, 602–610 (2024).
pubmed: 37936340
doi: 10.1111/dom.15349
Armstrong, D. G., Tan, T.-W., Boulton, A. J. M. & Bus, S. A. Diabetic foot ulcers: a review. JAMA 330, 62–75 (2023).
pubmed: 37395769
pmcid: 10723802
doi: 10.1001/jama.2023.10578
Hicks, C. W. & Selvin, E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr. Diab Rep. 19, 86 (2019).
pubmed: 31456118
pmcid: 6755905
doi: 10.1007/s11892-019-1212-8
Teo, Z. L. et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 128, 1580–1591 (2021).
pubmed: 33940045
doi: 10.1016/j.ophtha.2021.04.027
Mulder, H. Transcribing β-cell mitochondria in health and disease. Mol. Metab. 6, 1040–1051 (2017).
pubmed: 28951827
pmcid: 5605719
doi: 10.1016/j.molmet.2017.05.014
Festa, A. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42–47 (2000).
pubmed: 10880413
doi: 10.1161/01.CIR.102.1.42
Gado, M., Tsaousidou, E., Bornstein, S. R. & Perakakis, N. Sex-based differences in insulin resistance. J. Endocrinol. 261, e230245 (2024).
pubmed: 38265844
doi: 10.1530/JOE-23-0245
Petersen, K. F. et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl Acad. Sci. USA 103, 18273–18277 (2006).
pubmed: 17114290
pmcid: 1693873
doi: 10.1073/pnas.0608537103
Lear, S. A., Kohli, S., Bondy, G. P., Tchernof, A. & Sniderman, A. D. Ethnic variation in fat and lean body mass and the association with insulin resistance. J. Clin. Endocrinol. Metab. 94, 4696–4702 (2009).
pubmed: 19820012
doi: 10.1210/jc.2009-1030
Sylow, L., Tokarz, V. L., Richter, E. A. & Klip, A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 33, 758–780 (2021).
pubmed: 33826918
doi: 10.1016/j.cmet.2021.03.020
Smith, U. & Kahn, B. B. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J. Intern Med. 280, 465–475 (2016).
pubmed: 27699898
pmcid: 5218584
doi: 10.1111/joim.12540
Xie, Z., Xie, T., Liu, J., Zhang, Q. & Xiao, X. Emerging role of protein O-GlcNAcylation in liver metabolism: implications for diabetes and NAFLD. Int. J. Mol. Sci. 24, 2142 (2023).
pubmed: 36768465
pmcid: 9916810
doi: 10.3390/ijms24032142
Hart, G. W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80, 825–858 (2011).
pubmed: 21391816
pmcid: 3294376
doi: 10.1146/annurev-biochem-060608-102511
Chen, B. et al. Maternal inheritance of glucose intolerance via oocyte TET3 insufficiency. Nature 605, 761–766 (2022).
pubmed: 35585240
doi: 10.1038/s41586-022-04756-4
Epstein, F. H., Moller, D. E. & Flier, J. S. Insulin resistance—mechanisms, syndromes, and implications. N. Engl. J. Med. 325, 938–948 (1991).
doi: 10.1056/NEJM199109263251307
Jaldin-Fincati, J. R., Pavarotti, M., Frendo-Cumbo, S., Bilan, P. J. & Klip, A. Update on GLUT4 vesicle traffic: a cornerstone of insulin action. Trends Endocrinol. Metab. 28, 597–611 (2017).
pubmed: 28602209
doi: 10.1016/j.tem.2017.05.002
He, L. Alterations of gut microbiota by overnutrition impact gluconeogenic gene expression and insulin signaling. Int J. Mol. Sci. 22, 2121 (2021).
pubmed: 33672754
pmcid: 7924631
doi: 10.3390/ijms22042121
Poitout, V. & Robertson, R. P. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr. Rev. 29, 351–366 (2008).
pubmed: 18048763
doi: 10.1210/er.2007-0023
Weir, G. C. & Bonner-Weir, S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53, S16–S21 (2004).
pubmed: 15561905
doi: 10.2337/diabetes.53.suppl_3.S16
Shaikh, S. R., Beck, M. A., Alwarawrah, Y. & MacIver, N. J. Emerging mechanisms of obesity-associated immune dysfunction. Nat. Rev. Endocrinol. 20, 136–148 (2024).
pubmed: 38129700
doi: 10.1038/s41574-023-00932-2
Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808 (2003).
pubmed: 14679176
pmcid: 296995
doi: 10.1172/JCI200319246
Bays, H., Mandarino, L. & DeFronzo, R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89, 463–478 (2004).
pubmed: 14764748
doi: 10.1210/jc.2003-030723
Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635–645 (2012).
pubmed: 22560216
pmcid: 4156155
doi: 10.1016/j.cmet.2012.04.001
Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133–2223 (2018).
pubmed: 30067154
pmcid: 6170977
doi: 10.1152/physrev.00063.2017
Liu, P. et al. Role of macrophages in peripheral nerve injury and repair. Neural Regen. Res 14, 1335–1342 (2019).
pubmed: 30964051
pmcid: 6524518
doi: 10.4103/1673-5374.253510
El, F., Ka, N., Ts, J. & Dlh, B. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron 93, 1296–1313 (2017).
doi: 10.1016/j.neuron.2017.02.005
Oeckinghaus, A., Hayden, M. S. & Ghosh, S. Crosstalk in NF-κB signaling pathways. Nat. Immunol. 12, 695–708 (2011).
pubmed: 21772278
doi: 10.1038/ni.2065
Kracht, M., Müller-Ladner, U. & Schmitz, M. L. Mutual regulation of metabolic processes and proinflammatory NF-κB signaling. J. Allergy Clin. Immunol. 146, 694–705 (2020).
pubmed: 32771559
doi: 10.1016/j.jaci.2020.07.027
Villalobos-Labra, R., Subiabre, M., Toledo, F., Pardo, F. & Sobrevia, L. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol. Asp. Med. 66, 49–61 (2019).
doi: 10.1016/j.mam.2018.11.001
Prasad, M. K., Mohandas, S. & Ramkumar, K. M. Dysfunctions, molecular mechanisms, and therapeutic strategies of pancreatic β-cells in diabetes. Apoptosis 28, 958–976 (2023).
pubmed: 37273039
doi: 10.1007/s10495-023-01854-0
Qin, W. & Weng, J. Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis. Sci. Bull. (Beijing) 68, 1413–1429 (2023).
pubmed: 37336688
doi: 10.1016/j.scib.2023.06.003
Petersen, K. F. et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104, 12587–12594 (2007).
pubmed: 17640906
pmcid: 1924794
doi: 10.1073/pnas.0705408104
Bhat, O. M. et al. Interleukin-18-induced cell adhesion molecule expression is associated with feedback regulation by PPAR-γ and NF-κB in Apo E-/- mice. Mol. Cell Biochem. 428, 119–128 (2017).
pubmed: 28176248
doi: 10.1007/s11010-016-2922-8
Fu, Y., Wu, N. & Zhao, D. Function of NLRP3 in the Pathogenesis and Development of Diabetic Nephropathy. Med Sci. Monit. 23, 3878–3884 (2017).
pubmed: 28798291
pmcid: 5565226
doi: 10.12659/MSM.903269
Matoba, K. et al. Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease. Int J. Mol. Sci. 20, 3393 (2019).
pubmed: 31295940
pmcid: 6678414
doi: 10.3390/ijms20143393
Sheu, M. L. et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler. Thromb. Vasc. Biol. 25, 539–545 (2005).
pubmed: 15653566
doi: 10.1161/01.ATV.0000155462.24263.e4
Romeo, G., Liu, W.-H., Asnaghi, V., Kern, T. S. & Lorenzi, M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51, 2241–2248 (2002).
pubmed: 12086956
doi: 10.2337/diabetes.51.7.2241
Kowluru, R. A., Koppolu, P., Chakrabarti, S. & Chen, S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic. Res. 37, 1169–1180 (2003).
pubmed: 14703729
doi: 10.1080/10715760310001604189
Wu, M.-Y., Yiang, G.-T., Lai, T.-T. & Li, C.-J. The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxid. Med. Cell Longev. 2018, 3420187 (2018).
pubmed: 30254714
pmcid: 6145164
doi: 10.1155/2018/3420187
Chaurasia, S. S. et al. The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy. Sci. Rep. 8, 2847 (2018).
pubmed: 29434227
pmcid: 5809448
doi: 10.1038/s41598-018-21198-z
Dodington, D. W., Desai, H. R. & Woo, M. JAK/STAT—emerging players in metabolism. Trends Endocrinol. Metab. 29, 55–65 (2018).
pubmed: 29191719
doi: 10.1016/j.tem.2017.11.001
Tian, S., Zhao, H. & Song, H. Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. Crit. Rev. Food Sci. Nutr. 64, 5039–5056 (2022).
pubmed: 36397728
doi: 10.1080/10408398.2022.2148090
Bako, H. Y., Ibrahim, M. A., Isah, M. S. & Ibrahim, S. Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. Life Sci. 239, 117045 (2019).
pubmed: 31730866
doi: 10.1016/j.lfs.2019.117045
Zhang, H. et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. Kidney Int. 92, 909–921 (2017).
pubmed: 28554737
pmcid: 5610635
doi: 10.1016/j.kint.2017.03.027
Liu, Z. et al. Nobiletin suppresses high-glucose-induced inflammation and ECM accumulation in human mesangial cells through STAT3/NF-κB pathway. J. Cell Biochem. 120, 3467–3473 (2019).
pubmed: 30499124
doi: 10.1002/jcb.27621
Eg, L. et al. Interleukin 6 function in the skin and isolated keratinocytes is modulated by hyperglycemia. J. Immunol. Res. 2019, 5087847 (2019).
Ap, S. et al. Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing. Nat. Commun. 11, 4678 (2020).
doi: 10.1038/s41467-020-18276-0
Yung, J. H. M. & Giacca, A. Role of c-Jun N-terminal kinase (JNK) in obesity and type 2 diabetes. Cells 9, 706 (2020).
pubmed: 32183037
pmcid: 7140703
doi: 10.3390/cells9030706
Kitamura, T. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 9, 615–623 (2013).
pubmed: 23959366
doi: 10.1038/nrendo.2013.157
Back, S. H. & Kaufman, R. J. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev. Biochem. 81, 767–793 (2012).
pubmed: 22443930
pmcid: 3684428
doi: 10.1146/annurev-biochem-072909-095555
Gorman, A. M., Healy, S. J. M., Jäger, R. & Samali, A. Stress management at the ER: Regulators of ER stress-induced apoptosis. Pharm. Thers 134, 306–316 (2012).
doi: 10.1016/j.pharmthera.2012.02.003
Wang, Y., He, Z., Yang, Q. & Zhou, G. XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy. FEBS Open Bio 9, 1249–1258 (2019).
pubmed: 31077568
pmcid: 6609578
doi: 10.1002/2211-5463.12655
Yao, W. et al. IRE1α siRNA relieves endoplasmic reticulum stress-induced apoptosis and alleviates diabetic peripheral neuropathy in vivo and in vitro. Sci. Rep. 8, 2579 (2018).
pubmed: 29416111
pmcid: 5803253
doi: 10.1038/s41598-018-20950-9
Yang, L. et al. Role of endoplasmic reticulum stress in the loss of retinal ganglion cells in diabetic retinopathy. Neural Regen. Res. 8, 3148–3158 (2013).
pubmed: 25206636
pmcid: 4158709
Gupta, D., Kono, T. & Evans-Molina, C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes. Metab. 12, 1036–1047 (2010).
pubmed: 20977574
pmcid: 3764483
doi: 10.1111/j.1463-1326.2010.01299.x
Powers, S. K. & Schrager, M. Redox signaling regulates skeletal muscle remodeling in response to exercise and prolonged inactivity. Redox Biol. 54, 102374 (2022).
pubmed: 35738088
pmcid: 9233275
doi: 10.1016/j.redox.2022.102374
Petersen, K. F. et al. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. Proc. Natl Acad. Sci. USA 109, 8236–8240 (2012).
pubmed: 22547801
pmcid: 3361376
doi: 10.1073/pnas.1205675109
Lu, Q. et al. The mTOR promotes oxidative stress-induced apoptosis of mesangial cells in diabetic nephropathy. Mol. Cell Endocrinol. 473, 31–43 (2018).
pubmed: 29277549
doi: 10.1016/j.mce.2017.12.012
Samadi, M., Aziz, S. G.-G. & Naderi, R. The effect of tropisetron on oxidative stress, SIRT1, FOXO3a, and claudin-1 in the renal tissue of STZ-induced diabetic rats. Cell Stress Chaperones 26, 217–227 (2021).
pubmed: 33047279
doi: 10.1007/s12192-020-01170-5
Domingueti, C. P. et al. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J. Diabetes Complications 30, 738–745 (2016).
pubmed: 26781070
doi: 10.1016/j.jdiacomp.2015.12.018
Kang, Q. & Yang, C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 37, 101799 (2020).
pubmed: 33248932
pmcid: 7767789
doi: 10.1016/j.redox.2020.101799
Eid, S. A. et al. New perspectives in diabetic neuropathy. Neuron 111, 2623–2641 (2023).
pubmed: 37263266
pmcid: 10525009
doi: 10.1016/j.neuron.2023.05.003
Eid, S. A. et al. Targeting the NADPH oxidase-4 and liver X receptor pathway preserves Schwann cell integrity in diabetic mice. Diabetes 69, 448–464 (2020).
pubmed: 31882567
doi: 10.2337/db19-0517
Xu, J. et al. Oxidative stress induced by NOX2 contributes to neuropathic pain via plasma membrane translocation of PKCε in rat dorsal root ganglion neurons. J. Neuroinflammation 18, 106 (2021).
pubmed: 33952299
pmcid: 8101139
doi: 10.1186/s12974-021-02155-6
Jiao, Y. et al. MicroRNA-7a-5p ameliorates diabetic peripheral neuropathy by regulating VDAC1/JNK/c-JUN pathway. Diabet. Med. 40, e14890 (2023).
pubmed: 35616949
doi: 10.1111/dme.14890
Taylor, R. Type 2 diabetes. Diabetes Care 36, 1047–1055 (2013).
pubmed: 23520370
pmcid: 3609491
doi: 10.2337/dc12-1805
Samuel, V. T., Petersen, K. F. & Shulman, G. I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267–2277 (2010).
pubmed: 20609972
pmcid: 2995547
doi: 10.1016/S0140-6736(10)60408-4
Yao, Z. et al. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. Nat. Metab. 5, 1706–1725 (2023).
pubmed: 37735236
pmcid: 10590755
doi: 10.1038/s42255-023-00896-7
Geisler, C. E. et al. Hepatocyte membrane potential regulates serum insulin and insulin sensitivity by altering hepatic GABA release. Cell Rep. 35, 109298 (2021).
pubmed: 34192533
pmcid: 8341405
doi: 10.1016/j.celrep.2021.109298
Das, A. & Reis, F. mTOR signaling: new insights into cancer, cardiovascular diseases, diabetes and aging. Int J. Mol. Sci. 24, 13628 (2023).
pubmed: 37686434
pmcid: 10487471
doi: 10.3390/ijms241713628
Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).
pubmed: 28283069
pmcid: 5394987
doi: 10.1016/j.cell.2017.02.004
Leibowitz, G., Cerasi, E. & Ketzinel-Gilad, M. The role of mTOR in the adaptation and failure of β-cells in type 2 diabetes. Diabetes Obes. Metab. 10, 157–169 (2008).
pubmed: 18834443
doi: 10.1111/j.1463-1326.2008.00952.x
Qiao, S. et al. Bergenin impedes the generation of extracellular matrix in glomerular mesangial cells and ameliorates diabetic nephropathy in mice by inhibiting oxidative stress via the mTOR/β-TrcP/Nrf2 pathway. Free Radic. Biol. Med. 145, 118–135 (2019).
pubmed: 31494242
doi: 10.1016/j.freeradbiomed.2019.09.003
Bouçanova, F. et al. Disrupted function of lactate transporter MCT1, but not MCT4, in Schwann cells affects the maintenance of motor end-plate innervation. Glia 69, 124–136 (2021).
pubmed: 32686211
doi: 10.1002/glia.23889
Yang, H.-L., Tsai, Y.-C., Korivi, M., Chang, C.-T. & Hseu, Y.-C. Lucidone promotes the cutaneous wound healing process via activation of the PI3K/AKT, Wnt/β-catenin and NF-κB signaling pathways. Biochim. Biophys. Acta Mol. Cell Res. 1864, 151–168 (2017).
pubmed: 27816443
doi: 10.1016/j.bbamcr.2016.10.021
Wei, F. et al. Plasma endothelial cells-derived extracellular vesicles promote wound healing in diabetes through YAP and the PI3K/Akt/mTOR pathway. Aging (Albany NY) 12, 12002–12018 (2020).
pubmed: 32570219
doi: 10.18632/aging.103366
Jere, S. W., Houreld, N. N. & Abrahamse, H. Role of the PI3K/AKT (mTOR and GSK3β) signalling pathway and photobiomodulation in diabetic wound healing. Cytokine Growth Factor Rev. 50, 52–59 (2019).
pubmed: 30890300
doi: 10.1016/j.cytogfr.2019.03.001
Zhang, E., Gao, B., Yang, L., Wu, X. & Wang, Z. Notoginsenoside Ft1 promotes fibroblast proliferation via PI3K/Akt/mTOR signaling pathway and benefits wound healing in genetically diabetic mice. J. Pharm. Exp. Ther. 356, 324–332 (2016).
doi: 10.1124/jpet.115.229369
Kim, W., Shin, Y.-K., Kim, B.-J. & Egan, J. M. Notch signaling in pancreatic endocrine cell and diabetes. Biochem. Biophys. Res. Commun. 392, 247–251 (2010).
pubmed: 20035712
doi: 10.1016/j.bbrc.2009.12.115
Pajvani, U. B. et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat. Med. 19, 1054–1060 (2013).
pubmed: 23832089
pmcid: 3737382
doi: 10.1038/nm.3259
Pajvani, U. B. et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat. Med. 17, 961–967 (2011).
pubmed: 21804540
pmcid: 3387563
doi: 10.1038/nm.2378
Hasan, S. S. et al. Endothelial Notch signaling controls insulin transport in muscle. EMBO Mol. Med. 12, e09271 (2020).
pubmed: 32187826
pmcid: 7136962
doi: 10.15252/emmm.201809271
Siebel, C. & Lendahl, U. Notch signaling in development, tissue homeostasis, and disease. Physiol. Rev. 97, 1235–1294 (2017).
pubmed: 28794168
doi: 10.1152/physrev.00005.2017
Stumvoll, M., Goldstein, B. J. & Van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333–1346 (2005).
pubmed: 15823385
doi: 10.1016/S0140-6736(05)61032-X
Townsend, L. K. & Steinberg, G. R. AMPK and the endocrine control of metabolism. Endocr. Rev. 44, 910–933 (2023).
pubmed: 37115289
doi: 10.1210/endrev/bnad012
Steinberg, G. R. & Hardie, D. G. New insights into activation and function of the AMPK. Nat. Rev. Mol. Cell Biol. 24, 255–272 (2023).
pubmed: 36316383
doi: 10.1038/s41580-022-00547-x
Stromsdorfer, K. L. et al. NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 16, 1851–1860 (2016).
pubmed: 27498863
pmcid: 5094180
doi: 10.1016/j.celrep.2016.07.027
Tabák, A. G. et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care 35, 2540–2547 (2012).
pubmed: 22933430
pmcid: 3507593
doi: 10.2337/dc11-2263
Yc, H. et al. AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. Cell Death Dis. 12, 925 (2021).
doi: 10.1038/s41419-021-04184-8
Xu, J., Liu, L.-Q., Xu, L.-L., Xing, Y. & Ye, S. Metformin alleviates renal injury in diabetic rats by inducing Sirt1/FoxO1 autophagic signal axis. Clin. Exp. Pharm. Physiol. 47, 599–608 (2020).
doi: 10.1111/1440-1681.13226
Ren, H. et al. Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway. Mol. Cell Endocrinol. 500, 110628 (2020).
pubmed: 31647955
doi: 10.1016/j.mce.2019.110628
Gurung, M. et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51, 102590 (2020).
pubmed: 31901868
pmcid: 6948163
doi: 10.1016/j.ebiom.2019.11.051
Cox, A. J., West, N. P. & Cripps, A. W. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 3, 207–215 (2015).
pubmed: 25066177
doi: 10.1016/S2213-8587(14)70134-2
Wang, H. et al. The Wnt signaling pathway in diabetic nephropathy. Front. Cell Dev. Biol. 9, 701547 (2022).
pubmed: 35059392
pmcid: 8763969
doi: 10.3389/fcell.2021.701547
Zuriaga, M. A. et al. Activation of non-canonical WNT signaling in human visceral adipose tissue contributes to local and systemic inflammation. Sci. Rep. 7, 17326 (2017).
pubmed: 29229927
pmcid: 5725530
doi: 10.1038/s41598-017-17509-5
Nie, X., Wei, X., Ma, H., Fan, L. & Chen, W.-D. The complex role of Wnt ligands in type 2 diabetes mellitus and related complications. J. Cell Mol. Med. 25, 6479–6495 (2021).
pubmed: 34042263
pmcid: 8278111
doi: 10.1111/jcmm.16663
Zhang, H. et al. Regulatory mechanisms of the Wnt/β-catenin pathway in diabetic cutaneous ulcers. Front. Pharmacol. 9, 1114 (2018).
pubmed: 30386236
pmcid: 6199358
doi: 10.3389/fphar.2018.01114
Yamaguchi, Y. et al. Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in keratinocytes. FASEB J. 22, 1009–1020 (2008).
pubmed: 17984176
doi: 10.1096/fj.07-9475com
Catrina, S.-B. & Zheng, X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia 64, 709–716 (2021).
pubmed: 33496820
pmcid: 7940280
doi: 10.1007/s00125-021-05380-z
Koyasu, S., Kobayashi, M., Goto, Y., Hiraoka, M. & Harada, H. Regulatory mechanisms of hypoxia‐inducible factor 1 activity: Two decades of knowledge. Cancer Sci. 109, 560–571 (2018).
pubmed: 29285833
pmcid: 5834787
doi: 10.1111/cas.13483
Pitale, P. M. & Gorbatyuk, M. S. Diabetic retinopathy: from animal models to cellular signaling. Int J. Mol. Sci. 23, 1487 (2022).
pubmed: 35163410
pmcid: 8835767
doi: 10.3390/ijms23031487
Zhang, D., Lv, F.-L. & Wang, G.-H. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. Eur. Rev. Med. Pharm. Sci. 22, 5071–5076 (2018).
Ibar, C. & Irvine, K. D. Integration of Hippo-YAP signaling with metabolism. Dev. Cell 54, 256–267 (2020).
pubmed: 32693058
pmcid: 7373816
doi: 10.1016/j.devcel.2020.06.025
Taylor, R., Al-Mrabeh, A. & Sattar, N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 7, 726–736 (2019).
pubmed: 31097391
doi: 10.1016/S2213-8587(19)30076-2
Sun, T. & Han, X. Death versus dedifferentiation: the molecular bases of beta cell mass reduction in type 2 diabetes. Semin Cell Dev. Biol. 103, 76–82 (2020).
pubmed: 31831356
doi: 10.1016/j.semcdb.2019.12.002
Cinti, F. et al. Evidence of β-cell dedifferentiation in human type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 1044–1054 (2016).
pubmed: 26713822
doi: 10.1210/jc.2015-2860
Spijker, H. S. et al. Conversion of mature human β-cells into glucagon-producing α-cells. Diabetes 62, 2471–2480 (2013).
pubmed: 23569174
pmcid: 3712074
doi: 10.2337/db12-1001
Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 150, 1223–1234 (2012).
pubmed: 22980982
pmcid: 3445031
doi: 10.1016/j.cell.2012.07.029
Aguayo-Mazzucato, C. et al. Acceleration of β cell aging determines diabetes and senolysis improves disease outcomes. Cell Metab. 30, 129–142.e4 (2019).
pubmed: 31155496
pmcid: 6610720
doi: 10.1016/j.cmet.2019.05.006
Son, J. et al. Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure. Nat. Commun. 14, 558 (2023).
pubmed: 36732513
pmcid: 9895451
doi: 10.1038/s41467-023-36315-4
Liang, J., Chirikjian, M., Pajvani, U. B. & Bartolomé, A. MafA regulation in β-cells: from transcriptional to post-translational mechanisms. Biomolecules 12, 535 (2022).
pubmed: 35454124
pmcid: 9033020
doi: 10.3390/biom12040535
Ebrahim, N., Shakirova, K. & Dashinimaev, E. PDX1 is the cornerstone of pancreatic β-cell functions and identity. Front. Mol. Biosci. 9, 1091757 (2022).
pubmed: 36589234
pmcid: 9798421
doi: 10.3389/fmolb.2022.1091757
Ataie-Ashtiani, S. & Forbes, B. A review of the biosynthesis and structural implications of insulin gene mutations linked to human disease. Cells 12, 1008 (2023).
pubmed: 37048081
pmcid: 10093311
doi: 10.3390/cells12071008
Uchizono, Y., Alarcón, C., Wicksteed, B. L., Marsh, B. J. & Rhodes, C. J. The balance between proinsulin biosynthesis and insulin secretion: where can imbalance lead. Diabetes Obes. Metab. 9, 56–66 (2007).
pubmed: 17919179
doi: 10.1111/j.1463-1326.2007.00774.x
Cui, D. et al. Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes. Chin. Med. J. (Engl.) 137, 791 (2024).
pubmed: 38479993
doi: 10.1097/CM9.0000000000003034
Pascal, S. M. A., Guiot, Y., Pelengaris, S., Khan, M. & Jonas, J.-C. Effects of c-MYC activation on glucose stimulus-secretion coupling events in mouse pancreatic islets. Am. J. Physiol. Endocrinol. Metab. 295, E92–E102 (2008).
pubmed: 18413670
doi: 10.1152/ajpendo.90235.2008
Bensellam, M., Laybutt, D. R. & Jonas, J.-C. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions. Mol. Cell Endocrinol. 364, 1–27 (2012).
pubmed: 22885162
doi: 10.1016/j.mce.2012.08.003
Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y. & Takahashi, H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52, 581–587 (2003).
pubmed: 12606496
doi: 10.2337/diabetes.52.3.581
Lee, Y. et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl Acad. Sci. USA 91, 10878–10882 (1994).
pubmed: 7971976
pmcid: 45129
doi: 10.1073/pnas.91.23.10878
Maedler, K., Oberholzer, J., Bucher, P., Spinas, G. A. & Donath, M. Y. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 52, 726–733 (2003).
pubmed: 12606514
doi: 10.2337/diabetes.52.3.726
Brunham, L. R., Kruit, J. K., Verchere, C. B. & Hayden, M. R. Cholesterol in islet dysfunction and type 2 diabetes. J. Clin. Invest. 118, 403–408 (2008).
pubmed: 18246189
pmcid: 2214697
doi: 10.1172/JCI33296
Brunham, L. R. et al. β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13, 340–347 (2007).
pubmed: 17322896
doi: 10.1038/nm1546
Sturek, J. M. et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic β cells. J. Clin. Invest. 120, 2575 (2010).
pubmed: 20530872
pmcid: 2898593
doi: 10.1172/JCI41280
Maedler, K. et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851–860 (2002).
pubmed: 12235117
pmcid: 151125
doi: 10.1172/JCI200215318
Kim, E.-K. et al. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. Int J. Biochem Cell Biol. 39, 1260–1275 (2007).
pubmed: 17521952
doi: 10.1016/j.biocel.2007.04.005
Kaneto, H. et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 44, 733–738 (1995).
pubmed: 7540572
doi: 10.2337/diab.44.7.733
Li, X., Xiao, G.-Y., Guo, T., Song, Y.-J. & Li, Q.-M. Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications. Front. Endocrinol. (Lausanne) 13, 986565 (2022).
pubmed: 36387904
doi: 10.3389/fendo.2022.986565
Weng, Q. et al. STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia. Cell Death Differ. 27, 130–145 (2020).
pubmed: 31097787
doi: 10.1038/s41418-019-0344-3
Yang, B. et al. Macrophages and neutrophils are necessary for ER stress-induced β cell loss. Cell Rep. 40, 111255 (2022).
pubmed: 36001973
pmcid: 9444341
doi: 10.1016/j.celrep.2022.111255
Yang, B. et al. RIPK3-mediated inflammation is a conserved β cell response to ER stress. Sci. Adv. 6, eabd7272 (2020).
pubmed: 33355143
pmcid: 11206196
doi: 10.1126/sciadv.abd7272
Chung, S. S. et al. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells. Am. J. Physiol. Endocrinol. Metab. 301, E912–E921 (2011).
pubmed: 21846907
doi: 10.1152/ajpendo.00120.2011
Tang, C. et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. Diabetologia 55, 1366–1379 (2012).
pubmed: 22396011
doi: 10.1007/s00125-012-2474-8
Hetz, C., Zhang, K. & Kaufman, R. J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 21, 421–438 (2020).
pubmed: 32457508
pmcid: 8867924
doi: 10.1038/s41580-020-0250-z
Sharma, R. B., Landa-Galván, H. V. & Alonso, L. C. Living dangerously: protective and harmful ER stress responses in pancreatic β-cells. Diabetes 70, 2431–2443 (2021).
pubmed: 34711668
pmcid: 8564401
doi: 10.2337/dbi20-0033
Zhang, Y. et al. THADA inhibition in mice protects against type 2 diabetes mellitus by improving pancreatic β-cell function and preserving β-cell mass. Nat. Commun. 14, 1020 (2023).
pubmed: 36823211
pmcid: 9950491
doi: 10.1038/s41467-023-36680-0
Ardestani, A. et al. MST1 is a novel regulator of apoptosis in pancreatic beta-cells. Nat. Med. 20, 385–397 (2014).
pubmed: 24633305
pmcid: 3981675
doi: 10.1038/nm.3482
Yuan, T. et al. Proproliferative and antiapoptotic action of exogenously introduced YAP in pancreatic β cells. JCI Insight 1, e86326 (2016).
pubmed: 27812538
pmcid: 5085606
doi: 10.1172/jci.insight.86326
Filippatos, T. D., Alexakis, K., Mavrikaki, V. & Mikhailidis, D. P. Nonalcoholic fatty pancreas disease: role in metabolic syndrome, ‘prediabetes,’ diabetes and atherosclerosis. Dig. Dis. Sci. 67, 26–41 (2022).
pubmed: 33469809
doi: 10.1007/s10620-021-06824-7
Tt, C. et al. Fatty pancreas is independently associated with subsequent diabetes mellitus development: a 10-year prospective cohort study. Clin. Gastroenterol. Hepatol. 20, 2013–2022 (2022).
Pinnick, K. E. et al. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obes. (Silver Spring) 16, 522–530 (2008).
doi: 10.1038/oby.2007.110
Gerst, F. et al. What role do fat cells play in pancreatic tissue? Mol. Metab. 25, 1–10 (2019).
pubmed: 31113756
pmcid: 6600604
doi: 10.1016/j.molmet.2019.05.001
Yu, T.-Y. & Wang, C.-Y. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J. Diabetes Investig. 8, 735–747 (2017).
pubmed: 28371475
pmcid: 5668526
doi: 10.1111/jdi.12665
Haataja, L., Gurlo, T., Huang, C. J. & Butler, P. C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 29, 303–316 (2008).
pubmed: 18314421
pmcid: 2528855
doi: 10.1210/er.2007-0037
Huang, C. et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56, 2016–2027 (2007).
pubmed: 17475933
doi: 10.2337/db07-0197
Montane, J., Klimek-Abercrombie, A., Potter, K. J., Westwell-Roper, C. & Bruce Verchere, C. Metabolic stress, IAPP and islet amyloid. Diabetes Obes. Metab. 14, 68–77 (2012).
pubmed: 22928566
doi: 10.1111/j.1463-1326.2012.01657.x
Montemurro, C. et al. IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function. Nat. Commun. 10, 2679 (2019).
pubmed: 31213603
pmcid: 6581914
doi: 10.1038/s41467-019-10444-1
Gunton, J. E. Hypoxia-inducible factors and diabetes. J. Clin. Invest. 130, 5063–5073 (2020).
pubmed: 32809974
pmcid: 7524477
doi: 10.1172/JCI137556
Gonzalez, F. J., Xie, C. & Jiang, C. The role of hypoxia-inducible factors in metabolic diseases. Nat. Rev. Endocrinol. 15, 21–32 (2018).
pubmed: 30275460
pmcid: 6624429
doi: 10.1038/s41574-018-0096-z
Yuan, T. et al. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes. Diabetologia 60, 668–678 (2017).
pubmed: 28004151
doi: 10.1007/s00125-016-4188-9
Ardestani, A., Lupse, B., Kido, Y., Leibowitz, G. & Maedler, K. mTORC1 signaling: a double-edged sword in diabetic β cells. Cell Metab. 27, 314–331 (2018).
pubmed: 29275961
doi: 10.1016/j.cmet.2017.11.004
Chen, J. et al. Role of Wnt signaling pathways in type 2 diabetes mellitus. Mol. Cell Biochem. 476, 2219–2232 (2021).
pubmed: 33566231
doi: 10.1007/s11010-021-04086-5
Bowen, A., Kos, K., Whatmore, J., Richardson, S. & Welters, H. J. Wnt4 antagonises Wnt3a mediated increases in growth and glucose stimulated insulin secretion in the pancreatic beta-cell line, INS-1. Biochem. Biophys. Res. Commun. 479, 793–799 (2016).
pubmed: 27687546
doi: 10.1016/j.bbrc.2016.09.130
Florez, J. C. et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355, 241–250 (2006).
pubmed: 16855264
pmcid: 1762036
doi: 10.1056/NEJMoa062418
Bartolome, A., Zhu, C., Sussel, L. & Pajvani, U. B. Notch signaling dynamically regulates adult β cell proliferation and maturity. J. Clin. Invest. 129, 268–280 (2019).
pubmed: 30375986
doi: 10.1172/JCI98098
Bartolomé, A. et al. Notch-mediated Ephrin signaling disrupts islet architecture and β cell function. JCI Insight 7, e157694 (2022).
pubmed: 35167496
pmcid: 8986078
doi: 10.1172/jci.insight.157694
Li, M. et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct. Target Ther. 7, 216 (2022).
pubmed: 35794109
pmcid: 9259665
doi: 10.1038/s41392-022-01073-0
Bergman, M. & Tuomilehto, J. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res. Clin. Pr. 210, 111636 (2024).
doi: 10.1016/j.diabres.2024.111636
Liu, Y. et al. Evidence from a systematic review and meta-analysis: classical impaired glucose tolerance should be divided into subgroups of isolated impaired glucose tolerance and impaired glucose tolerance combined with impaired fasting glucose, according to the risk of progression to diabetes. Front. Endocrinol. (Lausanne) 13, 835460 (2022).
pubmed: 35250886
doi: 10.3389/fendo.2022.835460
Twig, G. et al. Adolescent obesity and early-onset type 2 diabetes. Diabetes Care 43, 1487–1495 (2020).
pubmed: 32321731
doi: 10.2337/dc19-1988
Zhang, X. et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 33, 1665–1673 (2010).
pubmed: 20587727
pmcid: 2890379
doi: 10.2337/dc09-1939
Tabák, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009).
pubmed: 19515410
pmcid: 2726723
doi: 10.1016/S0140-6736(09)60619-X
Garvey, W. T. et al. Association of baseline factors with glycemic outcomes in GRADE: a comparative effectiveness randomized clinical trial. Diabetes Care 47, 562–570 (2024).
pubmed: 38285957
doi: 10.2337/dc23-1782
Ogurtsova, K. et al. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res. Clin. Pr. 183, 109118 (2022).
doi: 10.1016/j.diabres.2021.109118
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157–163 (2004).
doi: 10.1016/S0140-6736(03)15268-3
Prillaman, M. Why BMI is flawed—and how to redefine obesity. Nature 622, 232–233 (2023).
pubmed: 37821595
doi: 10.1038/d41586-023-03143-x
Jayedi, A., Soltani, S., Zargar, M. S., Khan, T. A. & Shab-Bidar, S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 370, m3324 (2020).
pubmed: 32967840
pmcid: 7509947
doi: 10.1136/bmj.m3324
National Institute for Health and Care Excellence (NICE). Obesity: Identification, Assessment and Management (NICE, 2023).
Charchar, F. J. et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J. Hypertens. 42, 23–49 (2024).
pubmed: 37712135
doi: 10.1097/HJH.0000000000003563
Xu, S. et al. Evaluation of the value of diabetes risk scores in screening for undiagnosed diabetes and prediabetes: a community-based study in southwestern China. Postgrad. Med. 132, 737–745 (2020).
pubmed: 32990128
doi: 10.1080/00325481.2020.1821234
Ortiz-Martínez, M. et al. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Curr. Diabetes Rep. 22, 95–115 (2022).
doi: 10.1007/s11892-022-01453-4
Laakso, M. Biomarkers for type 2 diabetes. Mol. Metab. 27S, S139–S146 (2019).
pubmed: 31500825
doi: 10.1016/j.molmet.2019.06.016
Sacks, D. B. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 69, 808–868 (2023).
pubmed: 37473453
doi: 10.1093/clinchem/hvad080
Caixeta, D. C. et al. Salivary molecular spectroscopy: a sustainable, rapid and non-invasive monitoring tool for diabetes mellitus during insulin treatment. PLoS ONE 15, e0223461 (2020).
pubmed: 32182246
pmcid: 7077825
doi: 10.1371/journal.pone.0223461
Ascaso, F. J. & Huerva, V. Noninvasive continuous monitoring of tear glucose using glucose-sensing contact lenses. Optom. Vis. Sci. 93, 426–434 (2016).
pubmed: 26390345
doi: 10.1097/OPX.0000000000000698
Lee, H. et al. Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module. Sci. Adv. 3, e1601314 (2017).
pubmed: 28345030
pmcid: 5342654
doi: 10.1126/sciadv.1601314
Shilo, S. et al. Continuous glucose monitoring and intrapersonal variability in fasting glucose. Nat. Med. 30, 1424–1431 (2024).
pubmed: 38589602
doi: 10.1038/s41591-024-02908-9
Durnwald, C. et al. Continuous Glucose Monitoring Profiles in Pregnancies With and Without Gestational Diabetes Mellitus. Diabetes Care https://doi.org/10.2337/dc23-2149
Ferrannini, E. et al. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab. 90, 493–500 (2005).
pubmed: 15483086
doi: 10.1210/jc.2004-1133
Ziegler, D. et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31, 464–469 (2008).
pubmed: 18039804
doi: 10.2337/dc07-1796
Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 24, 137–144 (2007).
pmcid: 2267935
doi: 10.1111/j.1464-5491.2007.02043.x
Pan, X. R. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20, 537–544 (1997).
pubmed: 9096977
doi: 10.2337/diacare.20.4.537
Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343–1350 (2001).
pubmed: 11333990
doi: 10.1056/NEJM200105033441801
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
pubmed: 11832527
doi: 10.1056/NEJMoa012512
Ramachandran, A. et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49, 289–297 (2006).
pubmed: 16391903
doi: 10.1007/s00125-005-0097-z
Hamman, R. F. et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29, 2102–2107 (2006).
pubmed: 16936160
doi: 10.2337/dc06-0560
Gong, Q. et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 7, 452–461 (2019).
pubmed: 31036503
pmcid: 8172050
doi: 10.1016/S2213-8587(19)30093-2
Li, G. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2, 474–480 (2014).
pubmed: 24731674
doi: 10.1016/S2213-8587(14)70057-9
Lindström, J. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673–1679 (2006).
pubmed: 17098085
doi: 10.1016/S0140-6736(06)69701-8
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 3, 866–875 (2015).
pmcid: 4623946
doi: 10.1016/S2213-8587(15)00291-0
Lee, C. G. et al. Effect of metformin and lifestyle interventions on mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 44, 2775–2782 (2021).
pubmed: 34697033
pmcid: 8669534
doi: 10.2337/dc21-1046
Chiasson, J.-L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072–2077 (2002).
pubmed: 12086760
doi: 10.1016/S0140-6736(02)08905-5
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096–1105 (2006).
doi: 10.1016/S0140-6736(06)69420-8
DeFronzo, R. A. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364, 1104–1115 (2011).
pubmed: 21428766
doi: 10.1056/NEJMoa1010949
Kernan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321–1331 (2016).
pubmed: 26886418
pmcid: 4887756
doi: 10.1056/NEJMoa1506930
Yaghi, S. et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Circulation 137, 455–463 (2018).
pubmed: 29084736
doi: 10.1161/CIRCULATIONAHA.117.030458
le Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399–1409 (2017).
pubmed: 28237263
doi: 10.1016/S0140-6736(17)30069-7
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).
pubmed: 33567185
doi: 10.1056/NEJMoa2032183
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).
pubmed: 35658024
doi: 10.1056/NEJMoa2206038
Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).
pubmed: 37952131
doi: 10.1056/NEJMoa2307563
Rossing, P. et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 10, 24–34 (2022).
pubmed: 34856173
doi: 10.1016/S2213-8587(21)00295-3
James, S. et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 3, EVIDoa2300286 (2024).
pubmed: 38320489
doi: 10.1056/EVIDoa2300286
Speight, J. et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol. 12, 61–82 (2024).
pubmed: 38128969
doi: 10.1016/S2213-8587(23)00347-9
Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).
pubmed: 35715995
doi: 10.1111/jebm.12474
Marx, N. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 39, 4043–4140 (2023).
doi: 10.1093/eurheartj/ehad192
ADVANCE Collaborative Group. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).
doi: 10.1056/NEJMoa0802987
Lachin, J. M. & Nathan, D. M. Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care 44, 2216–2224 (2021).
pubmed: 34548284
pmcid: 8929187
doi: 10.2337/dc20-3097
Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Circulation 119, 351–357 (2009).
pubmed: 19095622
doi: 10.1161/CIRCULATIONAHA.108.191305
Ismail-Beigi, F. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419–430 (2010).
pubmed: 20594588
pmcid: 4123233
doi: 10.1016/S0140-6736(10)60576-4
Goldenberg, J. Z. et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ 372, m4743 (2021).
pubmed: 33441384
pmcid: 7804828
doi: 10.1136/bmj.m4743
Riddle, M. C. et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 44, 2438–2444 (2021).
pubmed: 34462270
pmcid: 8929179
doi: 10.2337/dci21-0034
Bonekamp, N. E. et al. Leisure-time and occupational physical activity and health outcomes in cardiovascular disease. Heart 109, 686–694 (2023).
pubmed: 36270785
doi: 10.1136/heartjnl-2022-321474
Uusitupa, M. et al. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. Nutrients 11, 2611 (2019).
pubmed: 31683759
pmcid: 6893436
doi: 10.3390/nu11112611
Kirkpatrick, C. F., Liday, C. & Maki, K. C. The effects of carbohydrate-restricted dietary patterns and physical activity on body weight and glycemic control. Curr. Atheroscler. Rep. 22, 20 (2020).
pubmed: 32468247
doi: 10.1007/s11883-020-00838-8
Zhu, X. et al. The effect of physical activity on glycemic variability in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol. (Lausanne) 12, 767152 (2021).
pubmed: 34867812
doi: 10.3389/fendo.2021.767152
Liu, M. et al. Association of accelerometer-measured physical activity and its change with progression to chronic kidney disease in adults with type 2 diabetes and overweight/obesity. Br. J. Sports Med. 58, 313–319 (2024).
pubmed: 38320851
doi: 10.1136/bjsports-2023-107564
Sabag, A. et al. Timing of moderate to vigorous physical activity, mortality, cardiovascular disease, and microvascular disease in adults with obesity. Diabetes Care 47, 890–897 (2024).
pubmed: 38592034
pmcid: 11043226
doi: 10.2337/dc23-2448
Clavero-Jimeno, A. et al. Impact of lifestyle moderate-to-vigorous physical activity timing on glycemic control in sedentary adults with overweight/obesity and metabolic impairments. Obesity (Silver Spring) 32,1465–1473.
Hamaya, R. et al. Time- vs step-based physical activity metrics for health. JAMA Intern. Med. 184, 718–725 (2024).
pubmed: 38767892
doi: 10.1001/jamainternmed.2024.0892
Pavlou, V. et al. Effect of time-restricted eating on weight loss in adults with type 2 diabetes: a randomized clinical trial. JAMA Netw. Open 6, e2339337 (2023).
pubmed: 37889487
pmcid: 10611992
doi: 10.1001/jamanetworkopen.2023.39337
Delgado-Lista, J. et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399, 1876–1885 (2022).
pubmed: 35525255
doi: 10.1016/S0140-6736(22)00122-2
Cienfuegos, S. et al. Effects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity. Cell Metab. 32, 366–378.e3 (2020).
pubmed: 32673591
pmcid: 9407646
doi: 10.1016/j.cmet.2020.06.018
Horne, B. D., Grajower, M. M. & Anderson, J. L. Limited evidence for the health effects and safety of intermittent fasting among patients with type 2 diabetes. JAMA 324, 341–342 (2020).
pubmed: 32614382
doi: 10.1001/jama.2020.3908
Wilkinson, M. J. et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab. 31, 92–104.e5 (2020).
pubmed: 31813824
doi: 10.1016/j.cmet.2019.11.004
Carter, S., Clifton, P. M. & Keogh, J. B. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw. Open 1, e180756 (2018).
pubmed: 30646030
pmcid: 6324303
doi: 10.1001/jamanetworkopen.2018.0756
Guo, L. et al. A 5:2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes: the early randomized clinical trial. JAMA Netw. Open 7, e2416786 (2024).
pubmed: 38904963
pmcid: 11193124
doi: 10.1001/jamanetworkopen.2024.16786
Chen, L. et al. High-fiber diet ameliorates gut microbiota, serum metabolism and emotional mood in type 2 diabetes patients. Front. Cell Infect. Microbiol. 13, 1069954 (2023).
pubmed: 36794003
pmcid: 9922700
doi: 10.3389/fcimb.2023.1069954
Wang, Y. et al. Effectiveness of mobile health interventions on diabetes and obesity treatment and management: systematic review of systematic reviews. JMIR Mhealth Uhealth 8, e15400 (2020).
pubmed: 32343253
pmcid: 7218595
doi: 10.2196/15400
DeMarsilis, A. et al. Pharmacotherapy of type 2 diabetes: an update and future directions. Metabolism 137, 155332 (2022).
pubmed: 36240884
doi: 10.1016/j.metabol.2022.155332
Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34, 1481–1486 (2011).
pubmed: 21593294
pmcid: 3120182
doi: 10.2337/dc10-2415
Elmaleh-Sachs, A. et al. Obesity management in adults: a review. JAMA 330, 2000–2015 (2023).
pubmed: 38015216
pmcid: 11325826
doi: 10.1001/jama.2023.19897
Lingvay, I., Sumithran, P., Cohen, R. V. & le Roux, C. W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 399, 394–405 (2022).
pubmed: 34600604
doi: 10.1016/S0140-6736(21)01919-X
Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753–2786 (2022).
pubmed: 36148880
pmcid: 10008140
doi: 10.2337/dci22-0034
Davies, M. et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397, 971–984 (2021).
pubmed: 33667417
doi: 10.1016/S0140-6736(21)00213-0
Davies, M. J. et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 314, 687–699 (2015).
pubmed: 26284720
doi: 10.1001/jama.2015.9676
Kosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394–1407 (2024).
pubmed: 38587233
doi: 10.1056/NEJMoa2313917
Garvey, W. T. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402, 613–626 (2023).
doi: 10.1016/S0140-6736(23)01200-X
Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).
pubmed: 29617641
doi: 10.1016/j.cmet.2018.03.001
Kim, K. S. et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science https://doi.org/10.1126/science.adj2537 (2024).
doi: 10.1126/science.adj2537
pubmed: 39325905
pmcid: 11232486
Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol. Metab. 57, 101351 (2021).
pubmed: 34626851
pmcid: 8859548
doi: 10.1016/j.molmet.2021.101351
Silveira, S. Q. et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J. Clin. Anesth. 87, 111091 (2023).
pubmed: 36870274
doi: 10.1016/j.jclinane.2023.111091
Garza, K. et al. Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study. Am. J. Gastroenterol. 119, 1081–1088 (2024).
pubmed: 38534127
Welk, B. et al. No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery. Diabetes Obes. Metab. https://doi.org/10.1111/dom.15711 (2024).
doi: 10.1111/dom.15711
pubmed: 38860419
Hiramoto, B. et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am. J. Gastroenterol. 119, 1126–1140 (2024).
pubmed: 38634551
Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).
pubmed: 28714183
doi: 10.1002/hep.29367
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 29, 101133 (2024).
Lee, B.-W. et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab. J. 44, 382–401 (2020).
pubmed: 32431115
pmcid: 7332334
doi: 10.4093/dmj.2020.0010
Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).
pubmed: 31279902
doi: 10.1016/j.jhep.2019.06.021
Ballestri, S. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31, 936–944 (2016).
pubmed: 26667191
doi: 10.1111/jgh.13264
Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70, 962–969 (2021).
pubmed: 32938692
doi: 10.1136/gutjnl-2020-322572
Sinn, D. H. et al. Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: a longitudinal cohort study. PLoS One 18, e0288820 (2023).
pubmed: 37463179
pmcid: 10353790
doi: 10.1371/journal.pone.0288820
Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297–2307 (2006).
pubmed: 17135584
doi: 10.1056/NEJMoa060326
Aithal, G. P. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135, 1176–1184 (2008).
doi: 10.1053/j.gastro.2008.06.047
Ratziu, V. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135, 100–110 (2008).
pubmed: 18503774
doi: 10.1053/j.gastro.2008.03.078
Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
pubmed: 20427778
pmcid: 2928471
doi: 10.1056/NEJMoa0907929
Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern Med. 165, 305–315 (2016).
pubmed: 27322798
doi: 10.7326/M15-1774
Bril, F. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 42, 1481–1488 (2019).
pubmed: 31332029
doi: 10.2337/dc19-0167
Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 177, 633–640 (2017).
pubmed: 28241279
pmcid: 5470366
doi: 10.1001/jamainternmed.2016.9607
Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554 (2015).
pubmed: 25125077
doi: 10.1002/hep.27368
Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).
pubmed: 25935633
doi: 10.1053/j.gastro.2015.04.043
Xie, Q. et al. Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review. Chin. Med. J. (Engl.) 136, 2014–2016 (2023).
pubmed: 37464470
doi: 10.1097/CM9.0000000000002778
Della Pepa, G. et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res. Clin. Pr. 178, 108984 (2021).
doi: 10.1016/j.diabres.2021.108984
Lutchman, G. et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol. 4, 1048–1052 (2006).
pubmed: 16814613
doi: 10.1016/j.cgh.2006.05.005
Alatas, F. S., Matsuura, T., Pudjiadi, A. H., Wijaya, S. & Taguchi, T. Peroxisome proliferator-activated receptor gamma agonist attenuates liver fibrosis by several fibrogenic pathways in an animal model of cholestatic fibrosis. Pediatr. Gastroenterol. Hepatol. Nutr. 23, 346–355 (2020).
pubmed: 32704495
pmcid: 7354870
doi: 10.5223/pghn.2020.23.4.346
Wang, S. et al. PPARγ regulates macrophage polarization by inhibiting the JAK/STAT pathway and attenuates myocardial ischemia/reperfusion injury in vivo. Cell Biochem. Biophys. 81, 349–358 (2023).
pubmed: 37129843
doi: 10.1007/s12013-023-01137-0
Liu, X., Zhang, P., Song, X., Cui, H. & Shen, W. PPARγ mediates protective effect against hepatic ischemia/reperfusion injury via NF-κB pathway. J. Invest. Surg. 35, 1648–1659 (2022).
pubmed: 35732295
doi: 10.1080/08941939.2022.2090033
Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).
pubmed: 26608256
doi: 10.1016/S0140-6736(15)00803-X
Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113–1124 (2021).
pubmed: 33185364
doi: 10.1056/NEJMoa2028395
Loomba, R. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 511–522 (2023).
pubmed: 36934740
pmcid: 10792518
doi: 10.1016/S2468-1253(23)00068-7
Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2401943 (2024).
doi: 10.1056/NEJMoa2401943
pubmed: 38856224
Sanyal, A. J. et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2401755 (2024).
doi: 10.1056/NEJMoa2401755
pubmed: 38856224
Tacke, F., Puengel, T., Loomba, R. & Friedman, S. L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J. Hepatol. 79, 552–566 (2023).
pubmed: 37061196
doi: 10.1016/j.jhep.2023.03.038
Nesti, L., Tricò, D., Mengozzi, A. & Natali, A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc. Diabetol. 20, 109 (2021).
pubmed: 34006325
pmcid: 8130304
doi: 10.1186/s12933-021-01294-7
Smith, S. R. et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54, 24–32 (2005).
pubmed: 15562376
doi: 10.1016/j.metabol.2004.07.008
Miyazaki, Y. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87, 2784–2791 (2002).
pubmed: 12050251
doi: 10.1210/jcem.87.6.8567
Cusi, K. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pr. 28, 528–562 (2022).
doi: 10.1016/j.eprac.2022.03.010
Duell, P. B. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb. Vasc. Biol. 42, e168–e185 (2022).
pubmed: 35418240
doi: 10.1161/ATV.0000000000000153
Chinese Society of Endocrinology & Chinese Diabetes Society. Management of Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease: an expert consensus (in Chinese). Chin. J. Endocrinol. Metab. 37, 589–598 (2021).
Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841–851 (2019).
pubmed: 31185157
doi: 10.1056/NEJMoa1901118
Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
pubmed: 31189511
doi: 10.1016/S0140-6736(19)31149-3
Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018).
pubmed: 30291013
doi: 10.1016/S0140-6736(18)32261-X
Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).
pubmed: 28910237
pmcid: 9792409
doi: 10.1056/NEJMoa1612917
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
pubmed: 27633186
doi: 10.1056/NEJMoa1607141
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
pubmed: 27295427
pmcid: 4985288
doi: 10.1056/NEJMoa1603827
Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).
pubmed: 26630143
doi: 10.1056/NEJMoa1509225
Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776–785 (2019).
pubmed: 31422062
doi: 10.1016/S2213-8587(19)30249-9
Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279–1289 (2005).
pubmed: 16214598
doi: 10.1016/S0140-6736(05)67528-9
Vaccaro, O. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 5, 887–897 (2017).
pubmed: 28917544
doi: 10.1016/S2213-8587(17)30317-0
Ahmadi, A., Panahi, Y., Johnston, T. P. & Sahebkar, A. Antidiabetic drugs and oxidized low-density lipoprotein: a review of anti-atherosclerotic mechanisms. Pharm. Res. 172, 105819 (2021).
doi: 10.1016/j.phrs.2021.105819
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
pubmed: 26378978
doi: 10.1056/NEJMoa1504720
Neal, B., Perkovic, V. & Matthews, D. R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 2099 (2017).
pubmed: 29166232
doi: 10.1056/NEJMoa1611925
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
pubmed: 30415602
doi: 10.1056/NEJMoa1812389
Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425–1435 (2020).
pubmed: 32966714
doi: 10.1056/NEJMoa2004967
Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129–139 (2021).
pubmed: 33200891
doi: 10.1056/NEJMoa2030186
Kenny, H. C. & Abel, E. D. Heart failure in type 2 diabetes mellitus: impact of glucose lowering agents, heart failure therapies and novel therapeutic strategies. Circ. Res. 124, 121–141 (2019).
pubmed: 30605420
pmcid: 6447311
doi: 10.1161/CIRCRESAHA.118.311371
Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).
pubmed: 36027570
doi: 10.1056/NEJMoa2206286
McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
pubmed: 31535829
doi: 10.1056/NEJMoa1911303
Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
pubmed: 34449189
doi: 10.1056/NEJMoa2107038
Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).
pubmed: 32865377
doi: 10.1056/NEJMoa2022190
Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117–128 (2021).
pubmed: 33200892
doi: 10.1056/NEJMoa2030183
Kahn, S. E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006).
pubmed: 17145742
doi: 10.1056/NEJMoa066224
Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125–2135 (2009).
pubmed: 19501900
doi: 10.1016/S0140-6736(09)60953-3
Erdmann, E. et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30, 2773–2778 (2007).
pubmed: 17666462
doi: 10.2337/dc07-0717
Lago, R. M., Singh, P. P. & Nesto, R. W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370, 1129–1136 (2007).
pubmed: 17905165
doi: 10.1016/S0140-6736(07)61514-1
Lincoff, A. M., Wolski, K., Nicholls, S. J. & Nissen, S. E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180–1188 (2007).
pubmed: 17848652
doi: 10.1001/jama.298.10.1180
van der Meer, R. W. et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 119, 2069–2077 (2009).
pubmed: 19349323
doi: 10.1161/CIRCULATIONAHA.108.803916
Dorkhan, M., Dencker, M., Stagmo, M. & Groop, L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol. 8, 15 (2009).
pubmed: 19298680
pmcid: 2664795
doi: 10.1186/1475-2840-8-15
Ferrannini, G. et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur. Heart J. 42, 2565–2573 (2021).
pubmed: 33197271
doi: 10.1093/eurheartj/ehaa777
Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G. & Molinero, G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur. J. Prev. Cardiol. 28, 69–75 (2021).
pubmed: 33606884
doi: 10.1093/eurjpc/zwaa074
Riley, D. R. et al. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes. Metab. 25, 2897–2909 (2023).
pubmed: 37385958
doi: 10.1111/dom.15185
Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20, 463–474 (2023).
pubmed: 36977782
doi: 10.1038/s41569-023-00849-3
Zhang, R., Xie, Q., Lu, X., Fan, R. & Tong, N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol. Metab. Syndr. 16, 99 (2024).
pubmed: 38735956
pmcid: 11089742
doi: 10.1186/s13098-024-01325-9
Wood, N. et al. Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction. Eur. J. Heart Fail 26, 925–935 (2024).
pubmed: 38468429
doi: 10.1002/ejhf.3192
Kasperova, B. J. et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc. Diabetol. 23, 223 (2024).
pubmed: 38943140
pmcid: 11214218
doi: 10.1186/s12933-024-02298-9
Xu, C. et al. Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors. J. Diabetes Complications 38, 108631 (2024).
pubmed: 38340519
doi: 10.1016/j.jdiacomp.2023.108631
Billing, A. M. et al. Metabolic communication by SGLT2 inhibition. Circulation 149, 860–884 (2024).
pubmed: 38152989
doi: 10.1161/CIRCULATIONAHA.123.065517
Jiang, Y. et al. Gut microbiota-tryptophan metabolism-GLP-1 axis participates in β-cell regeneration induced by dapagliflozin. Diabetes 73, 926–940 (2024).
pubmed: 38471012
pmcid: 11109800
doi: 10.2337/db23-0553
Anders, H.-J., Huber, T. B., Isermann, B. & Schiffer, M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat. Rev. Nephrol. 14, 361–377 (2018).
pubmed: 29654297
doi: 10.1038/s41581-018-0001-y
Shao, M. et al. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns. Diabetologia 67, 738–754 (2024).
pubmed: 38236410
doi: 10.1007/s00125-023-06078-0
Qiuxiao-Zhu et al. Protective effects and mechanisms of dapagliflozin on renal ischemia/reperfusion injury. Transpl. Immunol. 84, 102010 (2024).
pubmed: 38325526
doi: 10.1016/j.trim.2024.102010
Lu, Q. et al. Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway. Free Radic. Biol. Med. 195, 89–102 (2023).
pubmed: 36581059
doi: 10.1016/j.freeradbiomed.2022.12.088
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
pubmed: 30990260
doi: 10.1056/NEJMoa1811744
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
pubmed: 32970396
doi: 10.1056/NEJMoa2024816
Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).
pubmed: 38785209
doi: 10.1056/NEJMoa2403347
Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. https://doi.org/10.1038/s41591-024-03133-0 (2024).
doi: 10.1038/s41591-024-03133-0
pubmed: 39284953
pmcid: 11271413
Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).
pubmed: 28869249
doi: 10.1038/nrneph.2017.123
Lee, A. K. et al. Risk factors for severe hypoglycemia in black and white adults with diabetes: The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 40, 1661–1667 (2017).
pubmed: 28928117
pmcid: 5711330
doi: 10.2337/dc17-0819
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 102, S1–S127 (2022).
doi: 10.1016/j.kint.2022.06.008
Roddick, A. J. et al. UK Kidney Association Clinical Practice Guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 UPDATE. BMC Nephrol. 24, 310 (2023).
pubmed: 37880609
pmcid: 10598949
doi: 10.1186/s12882-023-03339-3
Cersosimo, E., Johnson, E. L., Chovanes, C. & Skolnik, N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes. Metab. 20, 497–507 (2018).
pubmed: 28862799
doi: 10.1111/dom.13108
Lim, S. et al. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study). Diabetes Obes. Metab. 19, 87–97 (2017).
pubmed: 27619558
doi: 10.1111/dom.12787
Pratley, R. E., Fleck, P. & Wilson, C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes. Metab. 16, 613–621 (2014).
pubmed: 24400655
doi: 10.1111/dom.12258
Jabbour, S. A. et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care 41, 2136–2146 (2018).
pubmed: 30082326
pmcid: 6150435
doi: 10.2337/dc18-0680
Matthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394, 1519–1529 (2019).
pubmed: 31542292
doi: 10.1016/S0140-6736(19)32131-2
Tuttle, K. R. et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 102, 248–260 (2022).
pubmed: 35661785
doi: 10.1016/j.kint.2022.05.012
Johnson, R. J. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a Scientific Workshop Organized by the National Kidney Foundation. Am. J. Kidney Dis. 71, 851–865 (2018).
pubmed: 29496260
pmcid: 7286363
doi: 10.1053/j.ajkd.2017.12.009
Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302–308 (2013).
pubmed: 23362314
pmcid: 3559486
doi: 10.1681/ASN.2012070718
Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252–2263 (2021).
pubmed: 34449181
doi: 10.1056/NEJMoa2110956
Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
pubmed: 33264825
doi: 10.1056/NEJMoa2025845
Ferro, C. J. et al. Lipid management in patients with chronic kidney disease. Nat. Rev. Nephrol. 14, 727–749 (2018).
pubmed: 30361677
doi: 10.1038/s41581-018-0072-9
Afshinnia, F. et al. Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. Ann. Clin. Transl. Neurol. 9, 1392–1404 (2022).
pubmed: 35923113
pmcid: 9463947
doi: 10.1002/acn3.51639
Pop-Busui, R. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 40, 136–154 (2017).
pubmed: 27999003
doi: 10.2337/dc16-2042
Wang, Y. et al. An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage. Biomed. Pharmacother. 133, 110991 (2021).
pubmed: 33227713
doi: 10.1016/j.biopha.2020.110991
Goodall, R. J. et al. A systematic review of the impact of foot care education on self efficacy and self care in patients with diabetes. Eur. J. Vasc. Endovasc. Surg. 60, 282–292 (2020).
pubmed: 32660807
doi: 10.1016/j.ejvs.2020.03.053
Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195–206 (2021).
pubmed: 33469209
pmcid: 9053333
doi: 10.1038/s41574-020-00451-4
World Health Organization. Classification of Diabetes Mellitus (World Health Organization, 2019).